Cargando…

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports

The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byun, Kyung-Do, Ahn, Sung Gwe, Baik, Hyung Joo, Lee, Anbok, Bae, Ki Beom, An, Min Sung, Kim, Kwang Hee, Shin, Jae Ho, Park, Ha Kyoung, Cho, Heunglae, Jeong, Joon, Kim, Tae Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929265/ https://www.ncbi.nlm.nih.gov/pubmed/27382400 http://dx.doi.org/10.4048/jbc.2016.19.2.214

Ejemplares similares

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Hypofractionated Radiotherapy for Early-Stage Breast Cancer: A Propensity Score Matched Analysis
por: Lee, Anbok, et al.
Publicado: (2022)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014)

Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient
por: Tsunogae, Marie, et al.
Publicado: (2021)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
por: Ishizaka, Takahiro, et al.
Publicado: (2023)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
por: Koczywas, M, et al.
Publicado: (2014)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection
por: Choi, Yunseon, et al.
Publicado: (2016)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
por: Agoulnik, Sergei I, et al.
Publicado: (2014)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
por: Papadaki, Maria A., et al.
Publicado: (2022)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
por: Tremblay, Gabriel, et al.
Publicado: (2015)

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
por: Adamo, Vincenzo, et al.
Publicado: (2019)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022)

Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients
por: Ko, Sung Min, et al.
Publicado: (2021)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
por: Vahdat, Linda T., et al.
Publicado: (2013)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
por: Ko, Hyemi, et al.
Publicado: (2022)

In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models
por: Baek, Yi-Yong, et al.
Publicado: (2021)

Association between obesity and local control of advanced rectal cancer after combined surgery and radiotherapy
por: Choi, Yunseon, et al.
Publicado: (2016)

Correction: Adverse effect of excess body weight on survival in cervical cancer patients after surgery and radiotherapy
por: Choi, Yunseon, et al.
Publicado: (2017)

Adverse effect of excess body weight on survival in cervical cancer patients after surgery and radiotherapy
por: Choi, Yunseon, et al.
Publicado: (2017)

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2014)

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers
por: Tono, Yasutaka, et al.
Publicado: (2018)

Efficacy of Surgical Treatment for Brain Metastasis in Patients with Non-Small Cell Lung Cancer
por: Kim, Sang Young, et al.
Publicado: (2015)

Metastasis-Free Interval Is Closely Related to Tumor Characteristics and Has Prognostic Value in Breast Cancer Patients with Distant Relapse
por: Kim, Hee Jun, et al.
Publicado: (2015)

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Local Control of Brain Metastasis: Treatment Outcome of Focal Brain Treatments in Relation to Subtypes
por: Chong, Jae Uk, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mauulir4seaqi2ehrq3qj2mt53